Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system

Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system

Importance: Adoption of novel therapeutics often lags for Black versus non-Hispanic White patients. Seminal clinical trials established the cardiovascular efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with type 2 di...

Full description

Saved in:
Bibliographic Details
Main Authors: Demetria M. Bolden, Vanessa Richardson, Taufiq Salahuddin, Kamal Henderson, Paul L. Hess, Sridharan Raghavan, David R. Saxon, P. Michael Ho, Stephen W. Waldo, Gregory G. Schwartz
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:American Journal of Preventive Cardiology
Subjects:
Type 2 diabetes
SGLT2i
GLP-1RA
Atherosclerotic cardiovascular disease
Pharmacoequity
Health disparity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666667725000388
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666667725000388

Similar Items